Every oncologist knows the feeling of watching a patient run out of time while a clinical trial crawls forward. The instinctive response is usually the same: we need to move faster. More trial sites. Shorter timelines. Fewer delays.
But here’s the uncomfortable truth: most oncology programs don’t fail because they moved too slowly. They fail because too many fundamental scientific questions remained unanswered.
In oncology, speed is rarely created by moving faster through development. More often, it is created by reducing uncertainty before development begins.
The Real Bottleneck Isn’t Time
When a drug program stalls or fails, the post-mortem often points to the same underlying issues: the wrong patients were enrolled, the biological target proved less important than expected, the optimal dose that was never fully understood, or resistance emerged sooner than anticipated.
These aren’t operational failures. They’re scientific ones.
Every oncology program begins with a series of critical questions. Does the target truly drive disease? Which patients are most likely to benefit? What dose achieves meaningful biological activity without unnecessary toxicity? How might resistance develop? How should the therapy fit into an increasingly complex treatment landscape?
Leave any of these questions unresolved and uncertainty begins to compound. One unanswered question several. By the time a pivotal trial begins, success depends not only on the therapy itself, but on a series of assumptions you made earlier.
Every unanswered scientific question eventually becomes a clinical question. Reducing uncertainty early doesn’t eliminate risk, but it makes development more predictable, and ultimately gives promising therapies a greater chance of reaching patients.[1]
Every Program Begins with Uncertainty
Uncertainty is an unavoidable part of innovation. Some programs explore entirely new biological mechanisms, whereas others build on well-characterized biology and still face uncertainty around patient selection, biomarkers, dosing strategies or therapeutic combinations.
The challenge is not whether uncertainty exists, but how much of it can be addressed before entering the clinic.
Novel mechanisms are particularly exciting because they have the potential to transform patient care. However, they also introduce additional questions. Is the biology truly disease-driving? Which patients should receive the therapy? Which biomarkers predict response? What resistance mechanisms are likely to emerge? How should the therapy be combined with existing standards of care?
These questions are not arguments against innovation. They are reminders that successful innovation depends on systematically reducing uncertainty throughout development rather than allowing it to accumulate.[2]
Reducing Uncertainty Before the Clinic
Modern oncology increasingly focuses on answering critical scientific questions as early as possible.
Advances in translational research, molecular profiling and biomarker development allow researchers to better understand disease biology before pivotal clinical trials begin. Early clinical studies can establish proof of mechanism, characterize pharmacology and help identify patients most likely to benefit.
This doesn’t eliminate uncertainty—drug development can never be completely predictable—but it changes its nature.
Programs that enter later-stage development with stronger biological rationale, clearer patient selection strategies and better characterized pharmacology are often better positioned to make confident development decisions.
Acceleration is therefore not simply about compressing timelines, but about entering development with fewer unanswered questions.
Dose Optimization as a Case Study
Dose selection illustrates how oncology thinking has evolved. For decades, oncology drug development largely followed a straightforward principle: identify the maximum tolerated dose and move forward.
While this approach made sense for many traditional cytotoxic therapies, it is not always appropriate for targeted therapies, where biological activity may plateau well below the maximum tolerated dose.
Recognizing this, the FDA’s Project Optimus initiative encourages sponsors to identify the biologically effective dose rather than simply the highest dose patients can tolerate. The objective is not only to improve tolerability, but to better understand the relationship between dose, biology, and clinical benefit before pivotal development begins.
Better dose optimization reduces uncertainty throughout development, It produces more predictable safety profiles, supports longer treatment duration where appropriate, and helps ensure that later-stage clinical trials evaluate therapies under conditions most likely to demonstrate meaningful patient benefit.[3][4]
Certainty as Infrastructure
Every major development decision is fundamentally a confidence decision. Are we sufficiently confident in the biology to continue investing? Do we understand which patients are most likely to respond? Have we selected the dose most likely to maximize benefit while minimizing unnecessary toxicity?
The more confidently these questions can be answered, the more efficient development becomes. Clinical trial design improves; resources are allocated more effectively; regulatory discussions become more focused; development decisions become more predictable.
Reducing uncertainty early is not conservative. It is one of the most patient-centric decisions a development team can make.
Every unsuccessful trial represents more than financial loss. It represents years during which patients continued to wait for better treatment options.[5]
What Speed Actually Looks Like
The oncology industry often talks about speed in terms of operational efficiency: faster enrollment, streamlined protocols, or shorter regulatory review timelines.
These improvements matter; but they are optimizations layered on top of something more fundamental.
Many of the fastest development programs move efficiently because critical scientific questions were answered long before the first patient was enrolled. They progress with greater confidence because target biology, patient selection, dose strategy and clinical rationale have already been strengthened.
This means the goal is not simply to move faster, it is to move forward with greater certainty.
What This Means Going Forward
Oncology is becoming more complex, not less. Tumour biology is increasingly understood at the molecular level, patient populations are becoming more precisely defined, and therapeutic strategies are becoming increasingly personalized.
In this environment, successful drug development will depend not only on generating new ideas, but on reducing uncertainty before those ideas reach the clinic. Programs built on stronger biological rationale, smarter patient selection and better-informed dose strategies are often better positioned to succeed — not because they are free of risk, but because they address it earlier.
At Helix BioPharma, we believe meaningful progress begins long before a pivotal clinical trial. It begins with a stronger scientific foundation, informed development decisions, and a commitment to understanding biology as deeply as possible.
Because in oncology, the fastest path to patients is often the one built on the strongest scientific foundations.
Ref:
1. Why early phase speed depends on oncology expertise. Worldwide Clinical Trials. April 20, 2026. Accessed June 16, 2026. https://www.worldwide.com/blog/2026/04/why-early%E2%80%91phase-speed-depends-on-oncology-expertise/
2. Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treat Rev. 2017;52:12-21. doi:10.1016/j.ctrv.2016.10.009
3. Fda.gov. Accessed June 16, 2026. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
4. Horning SJ, Haber DA, Selig WKD, et al. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res. 2013;19(16):4297-4304. doi:10.1158/1078-0432.CCR-13-0523
5. Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP. Optimal dosing for targeted therapies in oncology: Drug development cases leading by example. Clin Cancer Res. 2016;22(6):1318-1324. doi:10.1158/1078-0432.CCR-15-1295